Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q9XE
|
|||
| Former ID |
DIB009695
|
|||
| Drug Name |
MEDI4893
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ventilator-associated pneumonia [ICD-11: PK81.0] | Phase 2b | [1] | |
| Hospital-acquired pneumonia [ICD-11: CA40.Z] | Phase 1 | [2] | ||
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Alpha-hemolysin (Stap-coc hly) | Target Info | . | [2] |
| Reactome | The NLRP3 inflammasome | |||
| WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02296320) Study of the Efficacy and Safety of MEDI4893 | |||
| REF 2 | Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.